1. The People’s Republic of China, Administrative Measures on the Report and Monitoring of Adverse Drug Reactions. 2011. http://www.gov.cn/gongbao/content/2011/content_2004739.htm Accessed 15 Dec 2019.
2. WHO Technical Report No 498, World Health Organization. 1972. https://apps.who.int/iris/bitstream/handle/10665/40968/WHO_TRS_498.pdf?sequence=1&isAllowed=y. Accessed 15 Dec 2019.
3. European Commission. Council Directive 92/27/EEC on the labelling of medicinal products for human use and on package leaflets limits. (No. L113 of 31 March 1992). https://www.legislation.gov.uk/eudr/1992/27/pdfs/eudr_19920027_adopted_en.pdf. Accessed 29 Apr 2020.
4. Lal R, Kremzner M. Introduction to the new prescription drug labeling by the Food and Drug Administration. Am J Health Syst Pharm. 2007;64(23):2488–94.
5. Yu LX, Woodcock J. FDA pharmaceutical quality oversight. Int J Pharm. 2015;491(1–2):2–7.